Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr;29(2):127-136.
doi: 10.21147/j.issn.1000-9604.2017.02.05.

Helicobacter pylori antibody responses in association with eradication outcome and recurrence: a population-based intervention trial with 7.3-year follow-up in China

Tianyi Wang  1 , Yang Zhang  1 , Huijuan Su  1 , Zhexuan Li  1 , Lian Zhang  1 , Junling Ma  1 , Weidong Liu  1 , Tong Zhou  1 , Weicheng You  1 , Kaifeng Pan  1
Affiliations

Helicobacter pylori antibody responses in association with eradication outcome and recurrence: a population-based intervention trial with 7.3-year follow-up in China

Tianyi Wang et al. Chin J Cancer Res. 2017 Apr.

Abstract

Objective: To identify serum biomarkers that may predict the short or long term outcomes of anti-Helicobacter pylori (H. pylori) treatment, a follow-up study was performed based on an intervention trial in Linqu County, China.

Methods: A total of 529 subjects were selected randomly from 1,803 participants to evaluate total anti-H. pylori immunoglobulin G (IgG) and 10 specific antibody levels before and after treatment at 1-, 2- and 7.3-year. The outcomes of anti-H. pylori treatment were also parallelly assessed by13C-urea breath test at 45-d after treatment and 7.3-year at the end of follow-up.

Results: We found the medians of anti-H. pylori IgG titers were consistently below cut-off value through 7.3 years in eradicated group, however, the medians declined in recurrence group to 1.2 at 1-year after treatment and slightly increased to 2.0 at 7.3-year. While the medians were significantly higher (>3.0 at 2- and 7.3-year) among subjects who failed the eradication or received placebo. For specific antibody responses, baseline seropositivities of FliD and HpaA were reversely associated with eradication failure [for FliD, odds ratio (OR)=0.44, 95% confidence interval (95% CI): 0.27-0.73; for HpaA, OR=0.32, 95% CI: 0.17-0.60]. The subjects with multiple positive specific antibodies at baseline were more likely to be successfully eradicated in a linear fashion (Ptrend=0.006).

Conclusions: Our study suggested that total anti-H. pylori IgG level may serve as a potential monitor of long-term impact on anti-H. pylori treatment, and priority forH. pylori treatment may be endowed to the subjects with multiple seropositive antibodies at baseline, especially for FliD and HapA.

Keywords: Helicobacter pylori; biomarker; recurrence; serology; treatment outcome.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

1
1
SerumHelicobacter pylori (H. pylori) immunoglobulin G (IgG) antibody titers by eradication outcome in Shandong Intervention Trial.
2
2
Sero-prevalence to the individualHelicobacter pylori (H. pylori) antigens before and after anti-H. pylori treatment by eradication outcome in Shandong Intervention Trial. *, P<0.05 when compared to baseline (in 1995) sero-prevalence.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ohata H, Kitauchi S, Yoshimura N, , et al. Progression of chronic atrophic gastritis associated withHelicobacter pylori infection increases risk of gastric cancer . Int J Cancer. 2004;109:138–43. doi: 10.1002/ijc.11680. [Ohata H, Kitauchi S, Yoshimura N, et al. Progression of chronic atrophic gastritis associated withHelicobacter pylori infection increases risk of gastric cancer. Int J Cancer 2004;109:138-43. <DOI: 10.1002/ijc.11680> <PMID: 14735480> ] - DOI - PubMed
    1. Helicobacter and Cancer Collaborative Group. Gastric cancer andHelicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts . Gut. 2001;49:347–53. [Helicobacter and Cancer Collaborative Group. Gastric cancer andHelicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001;49:347-53. <PMID: 11511555> ] - PMC - PubMed
    1. You WC, Brown LM, Zhang L, , et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J NatI Cancer Inst. 2006;98:974–83. doi: 10.1093/jnci/djj264. [You WC, Brown LM, Zhang L, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J NatI Cancer Inst 2006;98:974-83. <DOI: 10.1093/jnci/djj264> <PMID: 16849680>] - DOI - PubMed
    1. Wong BC, Lam SK, Wong WM, , et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial . JAMA. 2004;291:187–94. doi: 10.1001/jama.291.2.187. [Wong BC, Lam SK, Wong WM, et al.Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004;291:187-94. <DOI: 10.1001/jama.291.2.187> <PMID: 14722144> ] - DOI - PubMed
    1. Fukase K, Kato M, Kikuchi S, , et al. Effect of eradication ofHelicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial . Lancet. 2008;372:392–7. doi: 10.1016/S0140-6736(08)61159-9. [Fukase K, Kato M, Kikuchi S, et al. Effect of eradication ofHelicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008;372:392-7. <DOI: 10.1016/S0140-6736(08)61159-9> <PMID: 18675689> ] - DOI - PubMed

LinkOut - more resources